Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list
Publication date
2025-09
Authors
Costa, Enrico
van den Ham, H A
Leufkens, H.G.M.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Keywords
CFTR modulators, Cystic fibrosis, Elexacaftor/tezacaftor/ivacaftor, Equitable access, Essential medicines, Essential medicines list, Global Health, Medicines affordability, World health organization, Pediatrics, Perinatology, and Child Health, Pulmonary and Respiratory Medicine
Citation
Costa, E, van den Ham, H A & Leufkens, H G M 2025, 'Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list', Journal of Cystic Fibrosis, vol. 24, no. 5, pp. 920-922. https://doi.org/10.1016/j.jcf.2025.06.006